New blood treatment could make transfusions safer for heart surgery
NCT ID NCT03459287
First seen Jun 25, 2026 · Last updated Jun 26, 2026 · Updated 1 time
Summary
This study tested a special way to treat donated red blood cells to kill germs, called the INTERCEPT Blood System. It involved 581 people having complex heart surgery who needed blood transfusions. The goal was to see if this treated blood is as safe and works as well as regular blood, especially for kidney health.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Pathogen-reduced red blood cells (INTERCEPT Blood System)
What this could lead to
If successful, this could provide a safer blood transfusion option for patients undergoing heart surgery, reducing the risk of infections from donated blood.
What could go wrong
This is a completed Phase 3 trial, but the main focus is on kidney safety rather than a cure. The intervention is a blood processing method, not a new drug, so the impact is limited to transfusion safety.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ANEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Bridgeport Hospital
Bridgeport, Connecticut, 06610, United States
-
Duke University Health System
Durham, North Carolina, 27710, United States
-
Emory
Atlanta, Georgia, 30308, United States
-
Henry Ford Health System
Detroit, Michigan, 48202, United States
-
Houston Methodist
Houston, Texas, 77030, United States
-
Mayo-Rochester
Rochester, Minnesota, 55905, United States
-
Rhode Island Hospital
Providence, Rhode Island, 02903, United States
-
Stanford
Stanford, California, 94305, United States
-
Temple
Philadelphia, Pennsylvania, 19140, United States
-
University of California Los Angeles
Los Angeles, California, 90095, United States
-
University of Colorado Hospital
Aurora, Colorado, 80045, United States
-
University of Florida
Gainesville, Florida, 32611, United States
-
University of Kentucky
Lexington, Kentucky, 40356, United States
-
University of Michigan
Ann Arbor, Michigan, 48109, United States
-
University of Pittsburgh Medical Center
Pittsburgh, Pennsylvania, 15213, United States
-
University of Texas Southwestern
Dallas, Texas, 75390, United States
-
University of Virginia Health System
Charlottesville, Virginia, 22908, United States
-
Yale New Haven Hospital
New Haven, Connecticut, 06510, United States